BRAF and neoplasm: Case 1 underwent a SR through EETA (the tumor harbored the BRAF V600E mutation) and a subsequent adjuvant target therapy with Dobrafenib and Trametinib with a 40% reduction in tumor volume after 2 months and a 90% reduction after 5 months.